Progress and Paradigms in Multiple Myeloma Kenneth C. Anderson DOI: 10.1158/1078-0432.CCR-16-0625 Published 15 November 2016 Article Figures & Data Info & Metrics PDF Abstract Remarkable progress has been achieved in multiple myeloma, and patient median survival has been extended 3- to 4-fold. Specifically, there have been 18 newly approved treatments for multiple myeloma in the past 12 years, including seven in 2015, and the treatment paradigm and patient outcome have been transformed. The definition of patients

BY PAUL KLEUTGHEN Sorce : http://www.myelomacrowd.org/stem-cell-transplant-and-the-tp53-deletion-in-multiple-myeloma-patients/ Hate myeloma bone marrow biopsies? You’re not alone. Soon, the happy day may come where we don’t need them. A new article in the journal Science Translational Medicine describes a new testing method where single cells of peripheral blood can be analyzed for a myeloma diagnosis and genetic subtyping without the need to do a bone marrow biopsy. For myeloma patients, this is a significant breakthrough that makes initial diagnosis, monitoring

The European Commission approved elotuzumab in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM) in patients who have received at least one prior therapy. The approval was based on the results of the randomized, open-label, phase III ELOQUENT-2 study that evaluated elotuzumab in combination with lenalidomide and dexamethasone (ERd) versus lenalidomide and dexamethasone alone (Rd) in 646 patients. At three years, those treated with ERd had a higher rate of progression-free survival